OLD Second National Bank of Aurora Has $6.98 Million Stake in Eli Lilly and Company $LLY

OLD Second National Bank of Aurora raised its position in Eli Lilly and Company (NYSE:LLY) by 16.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,147 shares of the company’s stock after acquiring an additional 1,291 shares during the quarter. Eli Lilly and Company makes up about 1.4% of OLD Second National Bank of Aurora’s investment portfolio, making the stock its 20th largest holding. OLD Second National Bank of Aurora’s holdings in Eli Lilly and Company were worth $6,979,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of LLY. Greenspring Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $382,000. Nabity Jensen Investment Management Inc grew its holdings in Eli Lilly and Company by 1.3% during the third quarter. Nabity Jensen Investment Management Inc now owns 1,413 shares of the company’s stock worth $1,078,000 after purchasing an additional 18 shares during the period. Sage Advisors LLC increased its position in Eli Lilly and Company by 2.4% during the third quarter. Sage Advisors LLC now owns 19,430 shares of the company’s stock worth $14,825,000 after buying an additional 456 shares during the last quarter. Motco raised its stake in Eli Lilly and Company by 3.6% in the third quarter. Motco now owns 15,300 shares of the company’s stock valued at $11,674,000 after buying an additional 532 shares during the period. Finally, River Street Advisors LLC lifted its position in shares of Eli Lilly and Company by 26.6% in the third quarter. River Street Advisors LLC now owns 4,510 shares of the company’s stock valued at $3,441,000 after buying an additional 947 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Reports say Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion — a near‑term M&A catalyst that would add internal oncology/metabolism assets and signal management’s willingness to pay for growth. Eli Lilly nears deal for Ventyx
• Positive Sentiment: Lilly struck a multiyear collaboration and exclusive license with Nimbus Therapeutics to develop an oral obesity/metabolic candidate — strengthens Lilly’s oral obesity pipeline, a key revenue lever beyond injectable GLP‑1s. Lilly, Nimbus partner
• Positive Sentiment: Analyst and market commentary today emphasized momentum, fundamentals and underappreciated runway for Lilly’s obesity and AI‑driven R&D initiatives — supporting investor interest and multiple expansion. Eli Lilly’s 2026 Resolution
• Positive Sentiment: Positive Wall‑street/quant writeups (Zacks and other outlets) highlighted LLY as a momentum/growth pick — these pieces can amplify buying flows into an already strong name. Zacks momentum pick
• Neutral Sentiment: A Lilly partner, Aktis, is targeting up to an $840M valuation in a U.S. IPO — a signal of ecosystem strength around Lilly collaborations but not a direct lift to LLY fundamentals. Aktis IPO target
• Negative Sentiment: Indiana’s attorney general sued Lilly alleging inflated insulin prices — a legal/regulatory overhang that can pressure sentiment and raise potential remediation costs. Indiana sues Lilly
• Negative Sentiment: Competitive risk: Novo Nordisk began selling a $149 Wegovy pill in the U.S., prompting short‑term investor concern about market share and pricing pressure across the obesity market. Novo pill launch

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,063.95 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a 50-day simple moving average of $1,022.32 and a two-hundred day simple moving average of $855.22. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.05, a price-to-earnings-growth ratio of 0.75 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LLY. Deutsche Bank Aktiengesellschaft boosted their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, Wolfe Research increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Five research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.